These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 16036024)

  • 21. Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes.
    Albaghdadi M; Gheorghiade M; Pitt B
    Eur Heart J; 2011 Nov; 32(21):2626-33. PubMed ID: 21672933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renin-angiotensin-aldosterone system (RAAS) pharmacogenomics: implications in heart failure management.
    Beitelshees AL; Zineh I
    Heart Fail Rev; 2010 May; 15(3):209-17. PubMed ID: 18351457
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neurohumoral blockade in CHF management.
    Willenbrock R; Philipp S; Mitrovic V; Dietz R
    J Renin Angiotensin Aldosterone Syst; 2000 Sep; 1 Suppl 1():24-30. PubMed ID: 11967792
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sex differences in heart failure medications targeting the renin-angiotensin-aldosterone system.
    Nicolaou PA
    Eur J Pharmacol; 2021 Apr; 897():173961. PubMed ID: 33617824
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Meta-Analysis Evaluating the Effects of Renin-Angiotensin-Aldosterone System Blockade on Outcomes of Heart Failure With Preserved Ejection Fraction.
    Kuno T; Ueyama H; Fujisaki T; Briasouli A; Takagi H; Briasoulis A
    Am J Cardiol; 2020 Apr; 125(8):1187-1193. PubMed ID: 32081366
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypertension: renin-angiotensin-aldosterone system alterations.
    Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH
    Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute effects of angiotensin-converting enzyme inhibition versus angiotensin II receptor blockade on cardiac sympathetic activity in patients with heart failure.
    Azevedo ER; Mak S; Floras JS; Parker JD
    Am J Physiol Regul Integr Comp Physiol; 2017 Oct; 313(4):R410-R417. PubMed ID: 28679681
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The clinical potential of renin inhibitors and angiotensin antagonists.
    Cody RJ
    Drugs; 1994 Apr; 47(4):586-98. PubMed ID: 7516858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Have the renin-angiotensin-aldosterone system perturbations in cardiovascular disease been exhausted?
    Mansur SJ; Hage FG; Oparil S
    Curr Cardiol Rep; 2010 Nov; 12(6):450-63. PubMed ID: 20827517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blockade of the renin-angiotensin system. Effect on mortality in patients with left ventricular systolic dysfunction.
    Pitt B
    Cardiol Clin; 1994 Feb; 12(1):101-14. PubMed ID: 8181019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence and outcomes associated with early heart failure pharmacotherapy in patients with ongoing cardiogenic shock.
    van Diepen S; Reynolds HR; Stebbins A; Lopes RD; Džavík V; Ruzyllo W; Geppert A; Widimsky P; Ohman EM; Parrillo JE; Dauerman HL; Baran DA; Hochman JS; Alexander JH
    Crit Care Med; 2014 Feb; 42(2):281-8. PubMed ID: 23982033
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The renin-angiotensin-aldosterone system and its suppression.
    Ames MK; Atkins CE; Pitt B
    J Vet Intern Med; 2019 Mar; 33(2):363-382. PubMed ID: 30806496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Programs for continuing medical education: B session; 1. The pathophysiology of heart failure--is it the disease of the heart?].
    Kitakaze M
    Nihon Naika Gakkai Zasshi; 2014 Mar; 103(3):681-6. PubMed ID: 24796136
    [No Abstract]   [Full Text] [Related]  

  • 34. Contemporary medical management of systolic heart failure.
    Nair AP; Timoh T; Fuster V
    Circ J; 2012; 76(2):268-77. PubMed ID: 22240600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Update on therapy for heart failure.
    DiBianco R
    Am J Med; 2003 Oct; 115(6):480-8. PubMed ID: 14563505
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects.
    Blumenfeld JD; Sealey JE; Mann SJ; Bragat A; Marion R; Pecker MS; Sotelo J; August P; Pickering TG; Laragh JH
    Am J Hypertens; 1999 May; 12(5):451-9. PubMed ID: 10342782
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of angiotensin II in the evolution of diastolic heart failure.
    Chinnaiyan KM; Alexander D; McCullough PA
    J Clin Hypertens (Greenwich); 2005 Dec; 7(12):740-7. PubMed ID: 16330897
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of the renin-angiotensin-aldosterone system in heart failure: new insights from basic clinical research.
    Cleland JG; Morgan K
    Curr Opin Cardiol; 1996 May; 11(3):252-62. PubMed ID: 8835867
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?
    Athyros VG; Mikhailidis DP; Kakafika AI; Tziomalos K; Karagiannis A
    Expert Opin Pharmacother; 2007 Apr; 8(5):529-35. PubMed ID: 17376010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Time and technology will tell: the pathophysiologic basis of neurohormonal modulation in heart failure.
    Reed BN; Street SE; Jensen BC
    Heart Fail Clin; 2014 Oct; 10(4):543-57. PubMed ID: 25217430
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.